The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs

Veterinary Journal

Volumn 176, Issue 3, 2008, Pages 310-319

  Volk, Holger A ^a   Matiasek, Lara A ^b   Feliu Pascual, Alejandro Luján ^b   Platt, Simon R ^c   Chandler, Kate E ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b ANIMAL HEALTH TRUST   (United Kingdom)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Antiepileptic drug; Dog; Levetiracetam; Refractory; Seizure

Indexed keywords

BROMIDE; ETIRACETAM; GABAPENTIN; PHENOBARBITAL; TOPIRAMATE;

ADD ON THERAPY; AGGRESSION; ARTICLE; ATAXIA; BULIMIA; DOG DISEASE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; IDIOPATHIC DISEASE; MALE; NONHUMAN; OPEN STUDY; POLYDIPSIA; POLYURIA; PROSPECTIVE STUDY; SEDATION; SEIZURE; WEIGHT GAIN;

ANIMALS; ANTICONVULSANTS; BROMIDES; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; MALE; PHENOBARBITAL; PIRACETAM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 41749104485     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2007.03.002     Document Type: Article

References (67)

1. Alsaadi T.M., Shatzel A., Marquez A.V., Jorgensen J., and Farias S. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure-European Journal of Epilepsy 14 (2005) 139-142
2. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurology 3 (2004) 618-621
3. Ben Menachem E., Edrich P., Van Vleymen B., Sander J.W.A., and Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Research 53 (2003) 57-64
4. Benedetti M.S., Coupez R., Whomsley R., Nicolas J.M., Collart P., and Baltes E. Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34 (2004) 281-300
5. Berendt, M., 2004. Epilepsy. In: Vite, C.H. (Ed.), Braund's Clinical Neurology in Small Animals: Localization, Diagnosis and Treatment, International Veterinary Information Service, Ithaca, NY, USA (www.ivis.org), July 2004. http://www.ivis.org/advances/Vite/berendt/chapter_frm.asp?LA=1 (accessed 10 October 2006).
6. Berendt M., and Gram L. Epilepsy and seizure classification in 63 dogs: a reappraisal of veterinary epilepsy terminology. Journal of Veterinary Internal Medicine 13 (1999) 14-20
7. Boggs J.G., Nowack W.J., and Drinkard C.R. Analysis of the "honeymoon effect" in adult epilepsy patients. Epilepsia 41 (2000) 222
8. Briggs D.E., and French J.A. Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opinion on Drug Safety 3 (2004) 415-424
9. Brodie, M.G., Perucca, E., Ryvlin, P., Ben-Menachem, E., Meencke, H.J., 2007. Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68, 402-408.
10. Chandler K. Canine epilepsy: what can we learn from human seizure disorders?. The Veterinary Journal 172 (2006) 207-217
11. Cramer J.A., Fisher R., Ben Menachem E., French J., and Mattson R.H. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40 (1999) 590-600
12. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 15268-15273
13. Dayrell-Hart B., Tiches D., Vite C., and Steinberg S. Efficacy and safety of felbamate as an anticonvulsant in dogs with refractory seizures. Journal of Veterinary Internal Medicine 10 (1996) 174
14. Dewey C.W. Anticonvulsant therapy in dogs and cats. The Veterinary Clinics of North America. Small Animal Practice 36 (2006) 1107-1127
15. Dewey C.W., Guiliano R., Boothe D.M., Berg J.M., Kortz G.D., Joseph R.J., and Budsberg S.C. Zonisamide therapy for refractory idiopathic epilepsy in dogs. Journal of the American Animal Hospital Association 40 (2004) 285-291
16. Doheny H.C., Ratnaraj N., Whittington M.A., Jefferys J.G., and Patsalos P.N. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Research 34 (1999) 161-168
17. French J., di Nicola S., and Arrigo C. Fast and sustained efficacy of levetiracetam during titration and the first 3 months of treatment in refractory epilepsy. Epilepsia 46 (2005) 1304-1307
18. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., Theodore W.H., Bazil C., Stern J., Schachter S.C., Bergen D., Hirtz D., Montouris G.D., Nespeca M., Gidal B., Marks Jr. W.J., Turk W.R., Fischer J.H., Bourgeois B., Wilner A., Faught Jr. R.E., Sachdeo R.C., Beydoun A., and Glauser T.A. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1252-1260
19. French J.A., Kanner A.M., Bautista J., Abou-Khalil B., Browne T., Harden C.L., Theodore W.H., Bazil C., Stern J., Schachter S.C., Bergen D., Hirtz D., Montouris G.D., Nespeca M., Gidal B., Marks Jr. W.J., Turk W.R., Fischer J.H., Bourgeois B., Wilner A., Faught Jr. R.E., Sachdeo R.C., Beydoun A., and Glauser T.A. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 62 (2004) 1261-1273
20. Fuks B., Gillard M., Michel P., Lynch B., Vertongen P., Leprince P., Klitgaard H., and Chatelain P. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. European Journal of Pharmacology 478 (2003) 11-19
21. Gillard M., Chatelain P., and Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. European Journal of Pharmacology 536 (2006) 102-108
22. Gillard M., Fuks B., Michel P., Vertongen P., Massingham R., and Chatelain P. Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain. European Journal of Pharmacology 478 (2003) 1-9
23. Glien M., Brandt C., Potschka H., and Löscher W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43 (2002) 350-357
24. Govendir M., Perkins M., and Malik R. Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. Australian Veterinary Journal 83 (2005) 602-608
25. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Research 22 (1995) 207-213
26. Grosso S., Franzoni E., Coppola G., Iannetti P., Verrotti A., Cordelli D.M., Marchiani V., Pascotto A., Spalice A., Acampora B., Morgese G., and Balestri P. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 14 (2005) 248-253
27. Harden C. Safety profile of levetiracetam. Epilepsia 42 (2001) 36-39
28. Holt, G., Volk, H.A., Chandler, K., 2005. The use of a questionnaire to compare clinical characteristics and type of seizure occurring in 3 dog breeds with idiopathic epilepsy. In: Proceedings of 18th Annual European College of Veterinary Neurologist Symposium, Munich, Germany.
29. Hovinga C.A. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 21 (2001) 1375-1388
30. Isoherranen N., Yagen B., Soback S., Roeder M., Schurig V., and Bialer M. Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 42 (2001) 825-830
31. Johannessen S.I., Battino D., Berry D.J., Bialer M., Kramer G., Tomson T., and Patsalos P.N. Therapeutic drug monitoring of the newer antiepileptic drugs. Therapeutic Drug Monitoring 25 (2003) 347-363
32. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 42 (2001) 13-18
33. Klitgaard H., Matagne A., Gobert J., and Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. European Journal of Pharmacology 353 (1998) 191-206
34. Klitgaard H., and Pitkanen A. Antiepileptogenesis, neuroprotection, and disease modification in the treatment of epilepsy: focus on levetiracetam. Epileptic Disorders 5 Supp. 1 (2003) S9-S16
35. Krakow K., Walker M., Otoul C., and Sander J.W.A.S. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 56 (2001) 1772-1774
36. Licht B.G., Licht M.H., Harper K.M., Lin S., Curtin J.J., Hyson L.L., and Willard K. Clinical presentations of naturally occurring canine seizures: similarities to human seizures. Epilepsy and Behavior 3 (2002) 460-470
37. Löscher W. Pharmakologische Grundlagen zur Behandlung der Epilepsie bei Hund und Katze. Der Praktische Tierarzt 8 (2003) 574-586
38. Löscher W., and Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. European Journal of Pharmacology 232 (1993) 147-158
39. Löscher W., Honack D., and Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. Journal of Pharmacology and Experimental Therapeutics 284 (1998) 474-479
40. Löscher W., and Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47 (2006) 1253-1284
41. Lukyanetz E.A., Shkryl V.M., and Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 (2002) 9-18
42. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America 101 (2004) 9861-9866
43. Margineanu D.G., and Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacological Research 42 (2000) 281-285
44. Margineanu D.G., and Klitgaard H. Levetiracetam has no significant gamma-aminobutyric acid-related effect on paired-pulse interaction in the dentate gyrus of rats. European Journal of Pharmacology 466 (2003) 255-261
45. McColl E., Jacoby A., Thomas L., Soutter J., Bamford C., Steen N., Thomas R., Harvey E., Garratt A., and Bond J. Design and use of questionnaires: a review of best practice applicable to surveys of health service staff and patients. Health Technology Assessment 5 (2001) 1-256
46. Niespodziany I., Klitgaard H., and Margineanu D.G. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices. Neuroscience Letters 306 (2001) 5-8
47. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology and Therapeutics 85 (2000) 77-85
48. Platt S.R., Abrams V., Garosi L.S., Abramson C.J., Penderis J., De Stefani A., and Wieczorek L. Gabapentin Therapy for Refractory Idiopathic Epilepsy in Dogs. The Veterinary Record 159 (2007) 881-884
49. Podell M. Antiepileptic drug therapy. Clinical Techniques in Small Animal Practice 13 (1998) 185-192
50. Podell M., and Fenner W.R. Bromide therapy in refractory canine idiopathic epilepsy. Journal of Veterinary Internal Medicine 7 (1993) 318-327
51. Regesta G., and Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Research 34 (1999) 109-122
52. Reynolds E.H., Elwes R.D.C., and Shorvon S.D. Why Does Epilepsy Become Intractable - Prevention of Chronic Epilepsy. Lancet 2 (1983) 952-954
53. Riek S., Löscher W., Rundfeldt C., and Tipold A. Wirkung verschiedener antiepileptischer Substanzen beim Hund. Tierärztliche Praxis 3 (2002) 91-92
54. Rigo J.M., Hans G., Nguyen L., Rocher V., Belachew S., Malgrange B., Leprince P., Moonen G., Selak I., Matagne A., and Klitgaard H. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal. British Journal of Pharmacology 136 (2002) 659-672
55. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nature reviews. Neuroscience 5 (2004) 553-564
56. Sasa M., Yan H.D., Ishihara K., Nagayama T., and Serikawa T. Is levetiracetam distinct from conventional antiepileptic drugs in antiepileptogenic properties in spontaneous epileptic rats?. Epilepsia 46 (2005) 94-95
57. Schwartz-Porsche D., Löscher W., and Frey H.H. Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. Journal of Veterinary Pharmacology and Therapeutics 8 (1985) 113-119
58. Seegers U., Potschka H., and Löscher W. Lack of effects of prolonged treatment with phenobarbital or phenytoin on the expression of P-glycoprotein in various rat brain regions. European Journal of Pharmacology 451 (2002) 149-155
59. Sills G.J., Leach J.P., Fraser C.M., Forrest G., Patsalos P.N., and Brodie M.J. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. European Journal of Pharmacology 325 (1997) 35-40
60. Steinberg, M., Faissler, D., 2004. Levetiracetam therapy for longterm idiopathic epileptic dogs. In: Proceedings of the 22nd Annual American College of Veterinary Internal Medicine Forum.
61. Tong X., and Patsalos P.N. A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. British Journal of Pharmacology 133 (2001) 867-874
62. Trepanier L.A., Van Schoick A., Schwark W.S., and Carrillo J. Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996). Journal of the American Veterinary Medical Association 213 (1998) 1449-1453
63. Von Klopmann, T., Simon, D., Tipold, A., 2005. Zonisamide add-on therapy for canine refractory epilepsy: Benefit or "Honey -Moon Effect". In: Proceedings of 18th Annual European College of Veterinary Neurologist Symposium, Munich, Germany.
64. Wieser H.G., Blume W.T., Fish D., Goldensohn E., Hufnagel A., King D., Sperling M.R., Luders H., and Pedley T.A. ILAE Commission Report. Proposal for a new classification of outcome with respect to epileptic seizures following epilepsy surgery. Epilepsia 42 (2001) 282-286
65. Wilby J., Kainth A., Hawkins N., Epstein D., McIntosh H., McDaid C., Mason A., Golder S., O'Meara S., Sculpher M., Drummond M., and Forbes C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technology Assessment 9 (2005) 1-4
66. Yan H.D., Ji-qun C., Ishihara K., Nagayama T., Serikawa T., and Sasa M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia 46 (2005) 1170-1177
67. 2+ currents. Seizure 10 (2001) 279-286